[Current status of chemotherapy of pulmonary tuberculosis and its further prospectives].
D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury; D003523:Cycloserine / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004361:Drug Tolerance; D006474:Hemorrhagic Disorders / Q000139:chemically induced; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D007612:Kanamycin / Q000627:therapeutic use; D010670:Phenylthiourea / Q000031:analogs & derivatives / Q000627:therapeutic use; D011696:Purpura, Thrombocytopenic / Q000139:chemically induced; D011719:Pyrazines / Q000627:therapeutic use; D012008:Recurrence / Q000188:drug therapy; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D011719:Pyrazines; D007612:Kanamycin; D010670:Phenylthiourea; D003523:Cycloserine; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Gegenwärtiger Stand der Chemotherapie der Lungentuberkulose und ihre weitere Perspektive.